Main Article Content
A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing approved biological product. Regulatory guidelines are undergoing constant refinement for biosimilar development and approval. Companies and their outsourcing partners who are willing to enter into the biosimilar market should be aware of all the guidelines and challenges with respect to biosimilars so that they can quickly respond to any sort of queries. The prospect of cost savings and efficiency has made the biosimilar market to look attractive however the regulatory, technical and legal challenges remain. To place any medicinal product in market a marketing authorization must be issued by the regulating agency. The United States authorized the Biologics Price Competition and Innovation Act (BPCI) toward the finish of March 2010 to giving an application pathway to follow-on organic items under areas 7001 to 7003 of the Patient Protection and Affordable Care Act and furthermore classified in 42 USC 262(k). In India, Review Committee on Genetic Manipulation (RCGM) and Genetic Engineering Approval Committee (GEAC) of Central Drugs Standard Control Organization (CDSCO) is answerable for the turn of events and preclinical assessment of recombinant biologics drugs The main aim of issuing marketing authorization is to ensure the product is safe, effective and a high-quality medicine is available in the market. The aspiration of this study is to understand and compare the marketing authorization requirements of biosimilar product and in selected markets like US and India Through these comparisons.
Khraishi M, Stead D, Lukas M, Scotte F, Schmid H. Biosimilars: A multidisciplinary perspective. Clin Ther. 2016;38(5):1238- 49.
Global Biosimilar Market Outlook; 2018.
[Accessed on 11 Jan 2021]
Central Drugs Standard Control Organization- Biologics. Available:https://cdsco.gov.in/opencms/opencms/en/biologicals/
[Accessed on 15 Jan 2021]
Central Drug Standard Control Organisation - CliniExperts -CliniExperts [Internet]. [cited 2021 Aug 2]. Available:https://cliniexperts.com/india-regulatory-bodies/cdsco/
Developing biosimilars – The process and quality standards.
[Accessed on 6 Mar 2021]
PharmaBoardroom | Biosimilars & Biologics: India [Internet]. [cited 2021 Aug 2].
United States Food and Drug Administration - Biosimilars.
[Accessed on 21 feb 2021]
FDA Form 356h.
Guidelines on similar biologics Regulatory requirements for MAA in India.
[Accessed on 5 Feb 2021]
[Answer] Under the U.S. Department of Health and Human Services (HHS) and U.S. Food and Drug Administration (FDA) regulations what is the Institutional Review Board (IRB) charged with? Select all that apply. – AnswerTrivia.com [Internet]. [cited 2021 Aug 2].